Current Edition

Methods to Reduce Placebo Response in Antidepressant Treatment Trials

Exaggerated and highly variable placebo response remains one of the biggest challenges in the development of drugs for major depressive disorder, resulting in numerous failed and negative trials. Henry J. Riordan and Roland Avrumson at Worldwide Clinical Trials reveals the recent FDA guidance, which suggests that substantial responses are typically seen in placebo groups in antidepressant trials.